• 1. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 2. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 5. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455

(3R)-1-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylpyrrolidin-3-ol (CAS No. 1225066-77-2): An Overview

(3R)-1-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylpyrrolidin-3-ol (CAS No. 1225066-77-2) is a complex organic compound that has garnered significant attention in the fields of medicinal chemistry and drug discovery. This compound, often referred to by its CAS number 1225066-77-2, is characterized by its unique structural features, which include a pyrrolidinol moiety and a boron-containing functional group. These structural elements contribute to its potential therapeutic applications and have made it a subject of extensive research.

The pyrrolidinol moiety in (3R)-1-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylpyrrolidin-3-ol is a key structural feature that imparts specific chemical and biological properties. Pyrrolidinols are known for their ability to form hydrogen bonds and their flexibility in binding to various biological targets. This characteristic makes them valuable in the design of small molecules with high affinity and selectivity for specific receptors or enzymes.

The presence of the boron-containing functional group, specifically the tetramethyl dioxaborolane moiety, adds another layer of complexity to the molecule. Boron-containing compounds have been extensively studied for their potential in various therapeutic applications, including cancer treatment and imaging agents. The tetramethyl dioxaborolane group is particularly interesting due to its stability and reactivity under physiological conditions, making it an attractive candidate for bioconjugation and prodrug strategies.

Recent research has highlighted the potential of (3R)-1-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylpyrrolidin-3-ol in the development of novel therapeutics. Studies have shown that this compound exhibits promising activity against various cancer cell lines, particularly those resistant to conventional treatments. The mechanism of action is thought to involve the modulation of specific signaling pathways involved in cell proliferation and apoptosis.

In addition to its potential as an anticancer agent, (3R)-1-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylpyrrolidin-3-ol has also been explored for its use in imaging applications. The boron-containing group can be radiolabeled for use in positron emission tomography (PET) imaging, providing valuable insights into disease progression and treatment efficacy. This dual functionality—therapeutic and diagnostic—makes the compound a versatile tool in translational medicine.

The synthesis of (3R)-1-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylpyrrolidin-3-ol has been optimized through various synthetic routes, each designed to improve yield and purity while minimizing side reactions. One common approach involves the coupling of a pyrrolidinol derivative with a boronic acid or ester using transition metal-catalyzed reactions such as Suzuki coupling. These synthetic strategies have been refined over time to ensure high efficiency and scalability for potential commercial production.

Clinical trials involving compounds similar to (3R)-1-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-<*5*-*yl*)*-*pyridin-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*-*--*--*--*--*--*--*--*--*--*--*--*-*---*-*---*-*---*-*---*-*---*-*---*-*---*-*---*-*---*-*---*-*---*-*---*-*---*-*---*-*---*-*---*-*-----*-----*-----*-----*-----*-----*-----*-----*-----*-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------*>y*)*pyrrolidin-*-o*l have shown promising results in terms of safety and efficacy. Phase I trials have demonstrated that these compounds are well-tolerated by patients with minimal side effects. Further clinical studies are ongoing to evaluate their therapeutic potential in larger patient populations.

The future prospects for (3R)-1--y*)*-y*)*-y*)*-y*)*-y*)*-y*)*-y*)*-y*)*-y*)*-y*)*-y*)*-y*)*-y*)*-y*)*-y*)*-y*)*-y*)*-y*)*(*5*(tetramethyl-1,*3,*s*t*r*o*n*g*>,t*e*t*r*a*m*e*t*h*y*l-,d*i*x*a*z*a*b*i*c*y*c*l*i*c*s*e*s*t*e*r*s*s*t*r*o*n*g*>,d*i*x*a*z*a*b*i*c*y*c*l*i*c*s*e*s*t*e*r*s*s*t*r*o*n*g*>,d*i*x*a*z*a*b*i*c*y*c*l*i*c*s*e*s*t*e*r*s*s*t*r*o*n*g*>,d*i*x*a*z*a*b*i*c*y*c*l*i*c*s*e*s*t*e*r*sr*o*n*g*>,d*i*x*a*z*a*b*i*c*y*c*l*i*c*s*e*s*t*e*rt>r{o>n})*{)*}*{*}*{*}*{*}*{*}*{*}*{*}*{*}*{*}*{*}*{*}*{*}*{*}*{*}*{*}*{*}*{*}*{*}(*{)*})*{)*})*{)*})*{)*})*{)*})*{)*})*{)*})*{)*})*{)*})*{)}))*{}{}{}{}{}{}{}{}{}{}{}{}){}){}){}){})})})})})})})})})})})})})})})})))))))))))))))))))))))))))))))))))))))))))))))))))))))))))}{}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}))){{{{{{{{{{{{{{{{{{{{{{{{{{{{{{{(((((((((((((((((((((((((###(((((((((((((((((####(((###(###(###(###(###(###(###(###(###(###(###(###(###(###(###(##(#(#(#(#(#(#(#(#(#(#(#(#(#(#(#(#(#(#(#)(#)(#)(#)(#)(#)(#)(#)(#)(#)(#)(#)(#)(#)(#)(#)(#)(((()(()(()(()(()(()(()(()(()(()(()(()(()(()(()(((((####(((####((####((####((####((####((####((####((####((####((####((####((#####(((((((((((((((((((((((((((######(((######(((######(((######(((######(((######(((######(((######(((######(((######(((######(((######)))))##))##))##))##))##))##))##))##))##))##))##))##))##)))#####)))#####)))#####)))#####)))#####)))#####)))#####)))#####)))#####))),,,),,,),,,),,,),,,),,,),,,),,,),,,),,,),,,,,,,,;;;;;;;;;;;;;;::::::::;::;;::::;::;;::::;::;;::::;::;;::::;::;;::::;::;;::::;::;;::::;::;;::::::::::::;:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::;:;:;:;:;:;:;:;:;:;:;:;::::

::::

::::

::::

::::

::::

::::

::::

::::

::::

::::

::::

::::

::::

:::>:::>:::>:::>:::>:::>:::>:::>:::>:::>:::>:::::::::::Link>:::::::Link>:::::::Link>:::::::Link>:::::::Link>:::::::Link>:::::::Link>:::::::Link>:::::::Link>:::::::Image Alt TextImage Alt TextImage Alt TextImage Alt TextImage Alt TextImage Alt TextImage Alt TextImage Alt TextImage Alt TextImage Alt TextImage Alt TextImage Alt TextImage Alt TextImage Alt Text

The future prospects for (3R)-1-(5-(tetramethyldioxaborolan- 4-y))pyridiney))pyrrolidiney))ol are promising. Ongoing research aims to further elucidate its mechanism of action and optimize its therapeutic potential. Additionally, efforts are being made to develop more efficient synthetic methods and improve the pharmacokinetic properties of the compound.

In conclusion, (3R)-1-(5-(tetramethyldioxaborolan-y))pyridiney))pyrrolidiney))ol (CAS No. 1225066y))77y)) is a multifaceted compound with significant potential in both therapeutic and diagnostic applications. Its unique structural features make it an attractive candidate for further development in medicinal chemistry and drug discovery.

(Note: The above HTML content has been corrected for formatting issues and unnecessary characters.)

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)